Home / COVID-19 Coverage / URMC testing antiviral drug to treat COVID-19 patients

URMC testing antiviral drug to treat COVID-19 patients

1022557487_research-img-72dpi_5631_976x710The University of Rochester Medical Center announced today its participation in a clinical trial sponsored by the National Institute of Health to evaluate the safety and effectiveness of antiviral drug remdesivir for adult patients hospitalized with COVID-19.

Ann Falsey M.D. and Angela Branche M.D. lead the study alongside the URMC Vaccine Trials and Evaluation Unit (VTEU).

Remdesivir was developed by Gilead Sciences. It’s a broad-spectrum antiviral drug that has been tested in humans with the Ebola virus. Remdesivir has also been effective in treating illnesses caused by other coronaviruses like Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) in animals.

The trial is double-blind and placebo-controlled. Acute COVID-19 patients at Strong Memorial Hospital will be used in the study. In the future, the study may grow to include other antiviral treatments that the VTEU wants to test.

nsheldon@bridgetowermedia.com / (585) 363-7031

Leave a Reply

Your email address will not be published.


Check Also

2021 Best Law Firms

U.S. News & World Report – Best Lawyers released its annual list of Best Law Firms and the following local ...

Nimish Mohile

Telemedicine use in cancer care increases in pandemic (access required)

In pre-COVID days, except in rare instances of geographical distance or a lack of specialized oncologists, medical appointments for cancer ...



RDG+Partners announce the hiring of Rob Spatola as a consulting manager. He brings over 20 years of experience to the ...